Selection committee reviews project proposals

A committee with experts from science and economy chooses the best ideas with the most promising teams out of all submitted project proposals.

Selection Committee

Kzenon - fotolia

A committee with experts from science and economy chooses the best ideas with the most promising teams out of all submitted project proposals.

The project proposals for GO-Bio funding go through a two-phase procedure. Initially, an expert committee reviews all submitted ideas with representatives from the international biotechnology scene. After the first selection round, the chosen teams can submit detailed applications in the second phase and present their proposition to the committee. The outcome of this committee session is then suggested to the BMBF project as GO-Bio funding. As awarding authority, the final decision lies with the BMBF.

Evaluation criteria for the selection of project proposals:

  • The project should be original in terms of science and technology
  • It should have commercial utilization potential within a period of ten years for marketable products, processes or services
  • The designated project leader and the team should be suitably qualified and skilled

Members of the selection committee:Dr. Reinhard J. Ambros – (ex) Novartis International AG

Prof. Dr. Florian Gantner – C.H. Boehringer Sohn AG & Co. KG
Prof. Dr. Thomas Gottwald – Ovesco Endoscopy AG
Dr. Erich Greiner – Cedrus Therapeutics Inc.
Prof. Dr. Hugo Hämmerle – The Natural and Medical Sciences Institute (NMI) at the University of Tübingen
Dr. Ruth Maas – Autodisplay Biotech GmbH
Dr. Markus Manns – Union Investment Privatfonds GmbH
Prof. Dr. Helmut E. Meyer – (ex) Leibniz-Institute for Analytical Sciences - ISAS e. V.
Dr. Torsten Mummenbrauer – Hookipa Biotech AG
PD Dr. Stefan Rußwurm – Hufeland Clinic & Research Centre of Medical Technology and Biotechnology,
Bad Langensalza
Karlheinz Schmelig – CREATHOR VENTURE Management GmbH
Prof. Dr. Heike Walles – University Clinic Würzburg/Fraunhofer ISC
Prof. Dr. Albrecht Wendel – (ex) Interfaculty Centre for Pharmacogenomics and Pharma Research, University of Tübingen